GLP-1 Agents: evidence grades and FDA status
GLP-1 receptor agonists mimic the incretin hormone GLP-1 to lower blood sugar and curb appetite. They are the basis of approved drugs like semaglutide and tirzepatide and are among the most-compounded medications at 503B outsourcing facilities during FDA shortages. Every GLP-1 PeptideGrids tracks is below, with its independent evidence grade and current FDA status.
13 compounds graded
| Compound | Evidence | FDA status | Summary |
|---|---|---|---|
| Semaglutide | A | FDA approved | Semaglutide has the broadest and strongest human evidence base among GLP-1 receptor agonists currently approved for weight |
| Tirzepatide | A | FDA approved | Tirzepatide is approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), supported by an |
| Liraglutide | A | FDA approved | Liraglutide is an FDA-approved GLP-1 receptor agonist with a well-established evidence base across type 2 diabetes and obesity |
| Dulaglutide | A | FDA approved | Dulaglutide (Trulicity) is an FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes with an extensive clinical |
| Exenatide | B | Withdrawn | Exenatide was the first GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Byetta, twice-daily, in 2005; Bydureon, |
| Lixisenatide | B | Withdrawn | Lixisenatide (Adlyxin) is a short-acting GLP-1 receptor agonist that was FDA-approved in 2016 for type 2 diabetes and voluntarily |
| Albiglutide | B | Withdrawn | Albiglutide (Tanzeum) was a once-weekly GLP-1 receptor agonist approved by FDA in April 2014 for type 2 diabetes, and voluntarily |
| Retatrutide | B | Not FDA approved | Retatrutide is an investigational once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors, developed |
| Survodutide | B | Not FDA approved | Survodutide is an investigational once-weekly injectable dual agonist of the GLP-1 and glucagon receptors, developed by |
| Cagrilintide | B | Not FDA approved | Cagrilintide is an investigational once-weekly long-acting amylin analog developed by Novo Nordisk, studied primarily as a |
| CagriSema | B | Not FDA approved | CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) is an investigational once-weekly fixed-dose combination injection of an |
| Orforglipron | A | FDA approved | Orforglipron (brand name Foundayo) is a non-peptide oral small-molecule GLP-1 receptor agonist developed by Eli Lilly, approved |
| Mazdutide | B | Not FDA approved | Mazdutide (IBI362) is a once-weekly injectable dual agonist of the GLP-1 receptor and glucagon receptor (GCGR), developed by |
Evidence grades: Grade A: Approved and proven; Grade B: Human evidence, not approved for this use; Grade C: Preliminary or limited human evidence; Grade D: Preclinical or anecdotal only. How we grade. Browse the 503B facility directory for compounding sources.